Indivior Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 total net revenue $356 million, up 13% YoY
- ➤SUBLOCADE net revenue $267 million, up 22% YoY
- ➤Q3 adjusted EBITDA $211 million, up 76% YoY
- ➤FY2026 adjusted EBITDA guidance remains $700 million to $740 million
- ➤Supernus merger expected to close November 2, 2026, creating combined company SUPN
Expert Statements
Joe Ciaffoni, Chief Executive Officer of Indivior Pharmaceuticals, Inc.
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda. Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus’ future and its ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders.”
Ryan Preblick, Chief Financial Officer of Indivior Pharmaceuticals, Inc.
“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2,100 basis points year-over-year. Our strong results and the execution of our Indivior Action Agenda puts us on track to achieve our previously communicated 2026 financial guidance, excluding the impact of our pending acquisition. Strong cash generation brought cash and investments to $332 million at quarter end, adding to the financial strength we will bring to our merger with Supernus.”
* Q3’26 Total Net Revenue of $356 Million, Up 13% YoY * Record Quarterly Total SUBLOCADE® Net Revenue of $267 Million in Q3'26, Up 22% YoY * Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Income of $161 Million in Q3'26 * Record Quarterly Adjusted EBITDA of $211 Million in Q3'26, Up 76% YoY * Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59%, Up 2,100 Basis Points YoY * On Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026.
"In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda," said Joe Ciaffoni, Chief Executive Officer. "Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus’ future and its ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders."
Get started
Create a free account to read the full story.